基于DWI及<sup>18</sup>F-FDG PET-CT勾画胸段食管癌大体肿瘤体积变化与比较

doi:10.3760/cma.j.cn113030-20210209-00069

摘要
图/表
参考文献(25)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要目的探讨基于食管癌原发肿瘤弥散加权像(DWI)高信号区域指导个体化局部加量放疗的可行性。方法对比32例胸段食管癌患者放疗前和放疗第15次时增强3DCT、¹⁸F-FDG PET-CT及增强MRI定位扫描图像,基于放疗前和放疗中3DCT、PET-CT及基于MRI的DWI与T2WI融合图像勾画食管癌大体肿瘤体积(GTV)并分别定义为GTVCTpre和GTVCTdur、GTVPETpre和GTVPETdur、GTVDWIpre和GTVDWIdur,分别测量放疗前及放疗中标准摄取值(SUV)、代谢肿瘤体积(MTV)、病灶糖酵解总量(TLG)、表观弥散系数(ADC)并计算其变化。结果治疗前与治疗中基于PET-CT和DWI图像所勾画食管癌GTV体积及其变化与相应增强3DCT之间均呈正相关(均P<0.001);SUV、MTV、TLG、ADC差异均有统计学意义(均P<0.001);无论治疗前还是治疗中GTV的SUV与ADC、△SUV与△ADC均无相关性(均P>0.05);GTVPETpre与GTVDWIpre间适形指数(CI)明显高于GTVPETdur与GTVDWIdur间的CI (P<0.001);基于DWI的GTV最大径退缩率及体积退缩率均>基于PET者(24%∶14%,P=0.017;60%∶41%,P<0.001)。结论无论放疗前还是放疗中食管癌SUV与ADC值、△SUV与△ADC均无相关性;放疗中期基于PET-CT图像高FDG摄取区勾画的GTV与基于DWI高信号区勾画者空间位置差异明显,且后者GTV退缩率明显大于前者。因此,放疗中基于DWI高信号区的变化进行放疗后程食管癌局部加量照射的可行性并不明确。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李慧敏
	李建彬
	李奉祥
	张英杰
	李彦康
	郭延娈
	徐亮

关键词 ：弥散加权成像, 体层摄影术,正电子发射-X线计算机, 大体肿瘤体积, 食管肿瘤/局部加量照射

Abstract：Objective To evaluate the spatial position and functional parameters of¹⁸F-FDG PET-CT and diffusion-weighted imaging (DWI) before and during radiotherapy (RT) based on the medium of 3DCT in patients with esophageal cancer and to explore whether the high-signal area derived from DWI can be used for individualized definition of the volume in need of dose-escalation for esophageal cancer. Methods Thirty-two patients with esophageal cancer treated with concurrent chemoradiotherapy or neoadjuvant chemoradiation sequentially underwent repeated 3DCT,¹⁸F-FDG PET-CT and enhanced MRI scans before RT and at the 15^th time of RT. All images were fused with the 3DCT images by deformable registration. The gross tumor volume (GTV) was delineated based on PET Edge on the first and second 3DCT, PET-CT and DWI and corresponding T2-weighted MRI (T2W-MRI) fused images, and defined as GTVCTpre and GTVCTdur, GTVPETpre, GTVPETdur, GTVDWIpre and GTVDWIdur,respectively. SUV (SUVmax, SUVmean,SUVpeak), MTV, TLG, ADC (ADCmin and ADCmean) values and △SUV (△SUVmax, △SUVmean, △SUVpeak), △MTV, △TLG,△ADC (△ADCmean and △ADCmin) of lesions were measured before and during RT. Results The differences in SUV (SUVmax, SUVmean, SUVpeak), MTV, TLG, ADCmean and ADCmin of the GTV before and during RT were statistically significant (all P<0.001). The tumor ADC and SUV values before and during RT showed no significant correlation, and there was no correlation between △ADC and △SUV (both P>0.05). The conformity index (CI) of GTVPETpre to GTVDWIpre was significantly higher than that of GTVPETdur to GTVDWIdur (P<0.001). The shrinkage rate of maximum diameter (△LDDWI)(24%) and the shrinkage rate of tumor volume (VRRDWI)(60%) based on DWI during RT were significantly greater than the corresponding PET-based △LDPET (14%) and VRRPET (41%)(P=0.017 and P<0.001). Conclusions The location of high residual FDG uptake based on PET-CT yields poor spatial matching compared with the area with residual high signal based on DWI during RT. Tumor ADC and SUV values may play complementary roles as imaging markers for prediction of patterns of failure and for definition of the volume in need of dose-escalation. In addition, the shrinkage rates of tumor maximum diameter/volume based on DWI during RT are significantly faster than those based on PET-CT. Therefore, the feasibility of selecting boosting of the high signal area derived from DWI for individualized definition of the volume for esophageal cancer is not clear.

Key words： Diffusion-weighted imaging Tomography, positron emission-X-ray computed Gross tumor volume Esophageal neoplasm/dose escalation irradiation

收稿日期: 2021-02-09

ZTFLH:

基金资助:国家自然科学基金项目(81773287);山东省泰山学者计划(ts20190982)

通讯作者: 李建彬,Email:lijianbin@msn.com;李奉祥,Email:lifengxiangli@aliyun.com

引用本文:

李慧敏,李建彬,李奉祥等. 基于DWI及¹⁸F-FDG PET-CT勾画胸段食管癌大体肿瘤体积变化与比较[J]. 中华放射肿瘤学杂志, 2021, 30(12): 1238-1243.

Li Huimin,Li Jianbin,Li Fengxiang et al. Comparison of spatial location and dynamic changes of functional parameters of primary tumors of thoracic esophageal cancer based on DWI and ¹⁸F-FDG PET-CT before and during radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1238-1243.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20210209-00069 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I12/1238

[1] Zhou S, Zhang L, Luo L, et al. Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy[J]. Jpn J Clin Oncol, 2018, 48(9):815-821. DOI:10.1093/jjco/hyy099.
[2] Liu Q, Fu XL, Yu W, et al. Potential values of metabolic tumor volume and heterogeneity measured with ¹⁸F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy[J]. Nucl Med Commun, 2015, 36(5):423-429. DOI:10.1097/MNM.0000000000000267.
[3] Chang S, Kim SJ. Prediction of Recurrence and mortality of locally advanced esophageal cancer patients using pretreatment F-18 FDG PET/CT parameters:intratumoral heterogeneity, SUV, and volumetric parameters[J]. Cancer Biother Radiopharm, 2016, 31(1):1-6. DOI:10.1089/cbr.2015.1932.
[4] Nkhali L, Thureau S, Edet-Sanson A, et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer:Reducing target volumes to deliver higher radiotherapy doses[J]. Acta Oncol, 2015, 54(6):909-915. DOI:10.3109/0284186X.2014.973062.
[5] Yu W, Cai XW, Liu Q, et al. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18) FDG-PET/CT for esophageal cancer[J]. Radiother Oncol, 2015, 114(2):195-200. DOI:10.1016/j.radonc.2014.12.007.
[6] Li H, Li F, Li J, et al.comparison of gross target volumes based on four-dimensional CT, positron emission tomography-computed tomography, and magnetic resonance imaging in thoracic esophageal cancer[J]. Cancer Med, 2020, 9(15):5353-5361. DOI:10.1002/cam4.3072.
[7] Vollenbrock SE, Voncken F, Bartels LW, et al. Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer:a systematic review[J]. Radiother Oncol, 2020, 142:17-26. DOI:10.1016/j.radonc.2019.07.006.
[8] Goense L, Borggreve AS, Heethuis SE, et al. Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer[J]. Br J Radiol, 2018, 91(1086):20170710. DOI:10.1259/bjr.20170710.
[9] Zhao S, Guo W, Tan R, et al. Correlation between minimum apparent diffusion coefficient values and the histological grade of breast invasive ductal carcinoma[J]. Oncol Lett, 2018, 15(5):8134-8140. DOI:10.3892/ol.2018.8343.
[10] Button MR, Morgan CA, Croydon ES, et al. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2009, 73(3):818-823. DOI:10.1016/j.ijrobp.2008.04.062.
[11] Kim JY, Kim JJ, Hwangbo L, et al. Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer:association between intratumoral heterogeneity and recurrence risk[J]. Eur Radiol, 2020, 30(1):66-76. DOI:10.1007/s00330-019-06383-6.
[12] Boekhoff MR, Defize IL, Borggreve AS, et al. 3-Dimensional target coverage assessment for MRI guided esophageal cancer radiotherapy[J]. Radiother Oncol, 2020, 147:1-7. DOI:10.1016/j.radonc.2020.03.007.
[13] Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy:The Elekta Unity MR-linac concept[J]. Clin Transl Radiat Oncol, 2019, 18:54-59. DOI:10.1016/j.ctro.2019.04.001.
[14] Heijmen L, ter Voert EE, Oyen WJ, et al. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer[J/OL]. PLoS One, 2015, 10(4):e0120823. DOI:10.1371/journal.pone.0120823.
[15] Weber MA, Bender K, von Gall CC, et al. Assessment of diffusion-weighted MRI and ¹⁸F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction[J]. J Gastrointestin Liver Dis, 2013, 22(1):45-52.
[16] Shimizu D, Yuasa N, Miyake H, et al. Clinical significance of SUVmax on preoperative ¹⁸F-fluorodeoxyglucose positron emission tomography in patients who underwent R0-esophagectomy for esophageal cancer[J]. Nagoya J Med Sci, 2018, 80(3):401-409. DOI:10.18999/nagjms.80.3.401.
[17] Giganti F, Salerno A, Ambrosi A, et al. Prognostic utility of diffusion-weighted MRI in oesophageal cancer:is apparent diffusion coefficient a potential marker of tumour aggressiveness?[J]. Radiol Med, 2016, 121(3):173-180. DOI:10.1007/s11547-015-0585-2.
[18] Unterrainer M, Eze C, Ilhan H, et al. Recent advances of PET imaging in clinical radiation oncology[J]. Radiat Oncol, 2020, 15(1):88. DOI:10.1186/s13014-020-01519-1.
[19] Borggreve AS, Goense L, van Rossum P, et al. Preoperative prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal cancer using (18) F-FDG PET/CT and DW-MRI:a prospective multicenter study[J]. Int J Radiat Oncol Biol Phys, 2020, 106(5):998-1009. DOI:10.1016/j.ijrobp.2019.12.038.
[20] Vollenbrock SE, Voncken F, Bartels LW, et al. Diffusion-weighted MRI with ADC mapping for response prediction and assessment of oesophageal cancer:a systematic review[J]. Radiother Oncol, 2020, 142:17-26. DOI:10.1016/j.radonc.2019.07.006.
[21] van Rossum PS, van Lier AL, van Vulpen M, et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J]. Radiother Oncol, 2015, 115(2):163-170. DOI:10.1016/j.radonc.2015.04.027.
[22] Min M, Lee MT, Lin P, et al. Assessment of serial multi-parametric functional MRI (diffusion-weighted imaging and R2*) with (18) F-FDG-PET in patients with head and neck cancer treated with radiation therapy[J]. Br J Radiol, 2016, 89(1058):20150530. DOI:10.1259/bjr.20150530.
[23] Goense L, Heethuis SE, van Rossum P, et al. Correlation between functional imaging markers derived from diffusion-weighted MRI and ¹⁸F-FDG PET/CT in esophageal cancer[J]. Nucl Med Commun, 2018, 39(1):60-67. DOI:10.1097/MNM.0000000000000771.
[24] 刘长民. 磁共振动态增强成像预测食管癌同步放化疗疗效的价值及与乏氧、血管生成相关性的研究[D]. 济南:山东大学, 2017.
Liu CM. The study of predict the treatment sensitivity of concurrent chemoradiotherapy and hypoxia, angiogenesis correlation of dynamic contrast-enhanced magnetic resonance imaging on esophageal carcinoma[D]. Ji'nan:Shandong University, 2017.
[25] Yu CW, Chen XJ, Lin YH, et al. Prognostic value of (18) F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma[J]. Eur J Radiol, 2019, 120:108671. DOI:10.1016/j.ejrad.2019.108671.